GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
- Details
- Category: GlaxoSmithKline

Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.
Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression
- Details
- Category: Pfizer

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
- Details
- Category: Bayer

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
- Details
- Category: Sanofi

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030
- Details
- Category: AstraZeneca

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
- Details
- Category: Novartis

The transaction bolsters the Novartis RLT pipeline and expands the company's research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation.
U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- Details
- Category: Pfizer

More Pharma News ...
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
- AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
- Bayer and Aignostics to collaborate on next generation precision oncology
- AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease